Peptide content comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-06-11. Numbers and descriptions here follow the published literature rather than marketing material.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | N-terminal fragment of thymosin beta-4 |
| Residue count | Seven | Sequence LKKTETQ |
| Approximate mass | 889 Da | Acetylated seven-residue peptide |
| Common synonyms | TB4 fragment, TB500 | Not identical to full-length TB4 |
| Reported activity | Actin binding | Observed mainly in cell-free systems |
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
Both provinces of Negros are interconnected by major inter-provincial roads. In Bacolod, there are two main roads, namely Lacson Street to the north and Araneta Street to the south. Cities, especially the provincial capitals of Bacolod and Dumaguete, are being served by jeepneys and taxis. Tricycles are mainly used for short-distance travel, and is common in city barangays, smaller cities and towns. Bus stations are present in major cities and towns within the region. Vallacar Transit Corporation, which operates the Ceres buses, serves the whole island of Negros. There are regularly scheduled fast ferry and roll-on/roll-off services for the island region's coastal cities and towns.
=== High API gravity === API gravity, American Petroleum Institute gravity, is a reverse method to decide “the weight of petroleum liquids in comparison to water”. If the API gravity exceeds 10, the liquid will float on the water and is classified to light oil. Therefore, the higher API means the lighter crude oil and it is regarded as more precious than crude oil with lower API (heavier crude) as it generates more high-value products during refinery process. The API range of light crude is between 35 and 45, and BLCO has an API of 32.9.
=== Recurring === Isabella Rossellini as Franny Forst, Byron's estranged wife Nicola Peltz Beckham as Franny after the transformation John Carroll Lynch as FBI Supervisor Meyer Williams Patrick Luwis as Meyer after the transformation Rob Yang as Dr. Ray Lee, a scientist and the original developer of the "Beauty" drug who now works for Byron Ari Graynor as Dr. Diana Sterling, a roboticist and the creator of the "Deacons"
== D == dactinomycin - dalton - decarboxylation reaction - delta opioid receptor - denaturation (biochemistry) - dendrite - dendritic cell - dendritic spine - deoxyribonucleoprotein - deoxyribose - desmopressin - deuterium - developmental biology - dialysis (chemical) - diffusion - dimer - dinucleotide repeat - diploid - disaccharide - dissociation constant - disulfide bond - disulfide bridge - DNA - DNA fragmentation - DNA replication - DNA sequence - DNA topology - DNA transposable element - DNA virus - DNA-binding protein - dopamine D1 receptor - dopamine D2 receptor - dopamine receptor - double helix - Drosophila - drugs - dynorphin
Sources: en.wikipedia.org
=== Brand names === It was introduced under the brand names Quitaxon and Aponal by Boehringer and as Sinequan by Pfizer. Doxepin is marketed under many brand names worldwide, including: Adnor, Anten, Antidoxe, Colian, Deptran, Dofu, Doneurin, Dospin, Doxal, Doxepini, Doxesom, Doxiderm, Flake, Gilex, Ichderm, Li Ke Ning, Mareen, Noctaderm, Oxpin, Patoderm, Prudoxin, Qualiquan, Quitaxon, Sagalon, Silenor, Sinepin, Sinequan, Sinquan, and Zonalon. It is also marketed as a combination drug with levomenthol under the brand name Doxure.
Former Conservative Party minister Penny Mordaunt is to take up a role with British American Tobacco, as part of their Transformation Advisory Board. Having previously ruled out an electoral pact with Reform at a national level, when asked by BBC News if the same applies at a local level in relation to the upcoming council elections, Conservative leader Kemi Badenoch says that local leaders of her party "would be free to share power" with other parties to keep councils running. Asked a similar question later, Nigel Farage, leader of Reform UK, appears to reject the idea although he does say that there could be "working relationships" with other parties. 11 April – Publication of Rishi Sunak's Resignation Honours. They include peerages for Michael Gove, Alister Jack and Simon Hart, and knighthoods for Jeremy Hunt and James Cleverly. Starmer travels to Northern Ireland to meet First Minister Michelle O'Neill and Deputy First Minister Emma Little-Pengelly to discuss US trade tariffs. 12 April – Parliament is recalled to discuss emergency legislation to save the Scunthorpe Steelworks from closure. The legislation will see the UK government take control of the steelworks and preventing owners Jingye from closing it. Liberal Democrat MP Wera Hobhouse speaks of her "shock" after being refused entry to Hong Kong a few days earlier. Rail Minister Lord Peter Hendy refers himself to police after admitting he used a mobile phone while driving a vintage double-decker bus through London.
Sulfur dioxide can bind to metal ions as a ligand to form metal sulfur dioxide complexes, typically where the transition metal is in oxidation state 0 or +1. Many different bonding modes (geometries) are recognized, but in most cases, the ligand is monodentate, attached to the metal through sulfur, which can be either planar and pyramidal η1. As a η1-SO2 (S-bonded planar) ligand sulfur dioxide functions as a Lewis base using the lone pair on S. SO2 functions as a Lewis acids in its η1-SO2 (S-bonded pyramidal) bonding mode with metals and in its 1:1 adducts with Lewis bases such as dimethylacetamide and trimethyl amine. When bonding to Lewis bases the acid parameters of SO2 are EA = 0.51 and EA = 1.56.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.
The fragment contains an actin-binding motif, and cell-free experiments show that it can interact with monomeric actin. That observation is the basis for interest in cell migration and repair processes. Effects reported in animals are not established for humans.
Purity is usually stated by the supplier rather than fixed by a pharmacopoeial monograph, and typical listings report a percentage from reverse-phase HPLC. Independent verification is uncommon. Because no single accepted specification exists, comparisons between lots and between suppliers are difficult.
Sealed, desiccated and protected from light, at -20 °C or lower for long-term storage. Short-term storage at refrigerator temperature is common in working laboratories.